When Two Become One: Conformational Changes in FXR/RXR Heterodimers Bound to Steroidal Antagonists

ChemMedChem. 2023 Feb 14;18(4):e202200556. doi: 10.1002/cmdc.202200556. Epub 2022 Nov 30.

Abstract

Farnesoid X receptor (FXR) is a nuclear receptor with an essential role in regulating bile acid synthesis and cholesterol homeostasis. FXR activation by agonists is explained by an αAF-2-trapping mechanism; however, antagonism mechanisms are diverse. We discuss microsecond molecular dynamics (MD) simulations investigating our recently reported FXR antagonists 2a and 2 h. We study the antagonist-induced conformational changes in the FXR ligand-binding domain, when compared to the synthetic (GW4064) or steroidal (chenodeoxycholic acid, CDCA) FXR agonists in the FXR monomer or FXR/RXR heterodimer r, and in the presence and absence of the coactivator. Our MD data suggest ligand-specific influence on conformations of different FXR-LBD regions, including the α5/α6 region, αAF-2, and α9-11. Changes in the heterodimerization interface induced by antagonists seem to be associated with αAF-2 destabilization, which prevents both co-activator and co-repressor recruitment. Our results provide new insights into the conformational behaviour of FXR, suggesting that FXR antagonism/agonism shift requires a deeper assessment than originally proposed by crystal structures.

Keywords: bile acids; farnesoid X receptor; molecular dynamics simulations; nuclear receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chenodeoxycholic Acid / pharmacology
  • DNA-Binding Proteins* / chemistry
  • Ligands
  • Receptors, Cytoplasmic and Nuclear
  • Transcription Factors* / metabolism

Substances

  • Transcription Factors
  • DNA-Binding Proteins
  • Ligands
  • Receptors, Cytoplasmic and Nuclear
  • Chenodeoxycholic Acid